BioStock: Annexin confirms promising results and strengthens financial position

Annexin Pharmaceuticals announces that the phase IIa study with its drug candidate ANXV for the eye disease retinal vein occlusion (RVO) has achieved all primary objectives. The results confirm previously reported topline data, demonstrating strong signals of effect and a favourable safety profile. The company has also announced a capital raise of approximately SEK 50 million, primarily for continued investments in the RVO program, a focused clinical study on diabetic retinopathy, but also for studies exploring the potential of ANXV treatment in cancer and sickle cell anemia.

Read the article at biostock.se:

https://www.biostock.se/en/2025/02/annexin-confirms-promising-results-and-strengthens-financial-position/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se